Neumora Therapeutics Inc (NASDAQ: NMRA) is -33.49% lower on its value in year-to-date trading and has touched a low of $8.33 and a high of $21.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NMRA stock was last observed hovering at around $10.63 in the last trading session, with the day’s gains setting it 0.71%.
Currently trading at $11.34, the stock is 9.34% and -0.88% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.76 million and changing 6.68% at the moment leaves the stock -1.32% off its SMA200. NMRA registered -35.24% loss for a year compared to 6-month gain of 23.26%. The firm has a 50-day simple moving average (SMA 50) of $11.536 and a 200-day simple moving average (SMA200) of $11.521175.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 17.27% loss in the last 1 month and extending the period to 3 months gives it a -13.30%, and is 11.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.65% over the week and 6.53% over the month.
Neumora Therapeutics Inc (NMRA) has around 124 employees, a market worth around $1.83B and $0.00M in sales. Distance from 52-week low is 36.13% and -46.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-91.57%).
The EPS is expected to grow by 55.65% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
150.0 institutions hold shares in Neumora Therapeutics Inc (NMRA), with institutional investors hold 88.90% of the company’s shares. The shares outstanding are 160.48M, and float is at 55.35M with Short Float at 19.57%. Institutions hold 64.25% of the Float.
Neumora Therapeutics Inc (NMRA) Insider Activity
The most recent transaction is an insider sale by Fust Matthew K, the company’s Director. SEC filings show that Fust Matthew K sold 14,049 shares of the company’s common stock on Oct 18 ’24 at a price of $17.03 per share for a total of $0.24 million. Following the sale, the insider now owns 20100.0 shares.
Neumora Therapeutics Inc disclosed in a document filed with the SEC on Oct 17 ’24 that Fust Matthew K (Director) sold a total of 7,739 shares of the company’s common stock. The trade occurred on Oct 17 ’24 and was made at $17.01 per share for $0.13 million. Following the transaction, the insider now directly holds 20100.0 shares of the NMRA stock.
Still, SEC filings show that on Oct 18 ’24, Fust Matthew K (Director) Proposed Sale 14,049 shares at an average price of $17.03 for $0.24 million. The insider now directly holds shares of Neumora Therapeutics Inc (NMRA).
